FABP4 and type 2 diabetes mellitus: Importantly, multiple independent studies in humans carrying a low-expression variant of FABP4 demonstrated lower incidence of type 2 diabetes, decreased circulating triglycerides and cholesterol, and reduced incidence of cardiometabolic disease (8, 9).